爱尔兰爵士制药的defiteli多少钱一瓶？

Hepatic veno-occlusive disease (HVOD) is one of the serious complications after hematopoietic stem cell transplantation (HSCT), and the mortality rate in patients with severe HVOD can be as high as 100%. Defibrinoside () is a mixture of single-stranded oligonucleotides with anti-thrombotic and fibrinolytic effects. In recent years, multiple clinical research results have shown that defibrotide is a safe and effective drug for preventing and treating HVOD after HSCT.

Defiteli is the first drug approved by the FDA for the treatment of severe hepatic venular occlusion, a rare and fatal liver disease. The approval was based on a Phase 2 trial of 75 patients, a Phase 3 trial of 102 patients, and an expansion trial of an additional 351 patients. All patients in the trial were diagnosed with hepatic veno-occlusive disease and associated renal or pulmonary dysfunction after HSCT (hematopoietic stem cell transplantation). In the Phase 2 trial, 44% of patients survived 100 days after transplantation, compared with 38% in the Phase 3 trial, and 45% in the expanded trial, and the FDA noted in a report that the expected 100-day survival rate for patients with severe veno-occlusive disease who were not treated with defibrotide was 21%-31%.

How much does a bottle of Defiteli from Irish Jazz Pharmaceuticals cost?

The specification of Irish Jazz Pharmaceuticals plc is 200 mg, and the price is about $21,600.

Recommended related hot articles: /newsDetail/95261.html

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.